Diffuse-Large-B-Cell Lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma, an aggressive cancer with high metastasis rates. About 85% of tumors contain mutations in epigenetic modifiers, and often multiple hits are observed in one tumor. These mutations occur early in lymphogenesis and contribute to maintaining the highly proliferative germinal center program.
Our work mainly focuses on the contribution of EZH2 Gain-of-Function (Y646N) mutations to the epigenetic landscape and its combinatorial effects with mutations in other histone modifiers. We employ reverse genetics, molecular biology, drugs, and single-cell methods to study epigenetic trends, epigenetic populations, and the epigenetic network contributed by this mutation.
